Targeted therapies for myeloproliferative neoplasms

The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bing, Rampal, Raajit K., Xiao, Zhijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636147/
https://www.ncbi.nlm.nih.gov/pubmed/31346467
http://dx.doi.org/10.1186/s40364-019-0166-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636147/
https://www.ncbi.nlm.nih.gov/pubmed/31346467
http://dx.doi.org/10.1186/s40364-019-0166-y

Ejemplares similares